InvestorsHub Logo
Followers 43
Posts 6100
Boards Moderated 1
Alias Born 11/27/2009

Re: None

Monday, 03/20/2023 7:53:49 AM

Monday, March 20, 2023 7:53:49 AM

Post# of 589372
$PRVCF PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee

https://www.newsfilecorp.com/release/158992

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023, to complete the following.

Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond those already underway or in the planning stage) that will be needed to support a successful initial IND and/or CTA submission.
Construction of a clinical development plan for Phase 1 through pivotal Phase 3 studies.
Authoring of the Investigational Brochure for the Client's lead peptide in the final indication of interest.
PreveCeutical has now commenced the clinical development on March 20, 2023. This work is being performed at our selected CRO's facilities in Australia.

Furthermore, the board of directors appointed a disclosure committee represented by Stephen Van Deventer, Dr Linnea Olofsson and Evan Ballantyne effective immediately.

PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "As we continue to meet further milestones, we are enthusiastic that this program has commenced as we plan to aggressively pursue the development so we may apply for IND (Investigative New Drug) status and complete the Phase 1 clinical trials."
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.